{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=202090&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?uin=202090&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=202090&_metadata=all&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&uin=202090&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=202090&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?uin=202090&min-ddpModified.=2018-11-09T16%3A58%3A49.159Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1024698", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
      ], "answer" : {"_about" : "http://data.parliament.uk/resources/1024698/answer", "answerText" : {"_value" : "<p>Currently, rare diseases are defined as conditions affecting no more than five in 10,000 people in the European Union. The new European Clinical Trial Regulation (Regulation (EU) No 536/2014) will introduce an \u2018ultra-rare\u2019 condition and states that clinical trials for the development of orphan medicinal products and those of medicines affecting no more than one person in 50,000 in the EU (ultra-rare diseases) should be fostered, and in such areas, a rapid yet in-depth assessment is of particular importance. The new clinical trials regulation is expected to be implemented in the EU in late 2020. The Government has confirmed that United Kingdom law will remain aligned with the parts of the new EU clinical trials Regulation that are within the UK\u2019s control.<\/p>"}
        , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"}
        }
        , "answeringMemberConstituency" : {"_value" : "Thurrock"}
        , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"}
        , "dateOfAnswer" : {"_value" : "2018-12-20", "_datatype" : "dateTime"}
        , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
        , "questionFirstAnswered" : [{"_value" : "2018-12-20T17:10:46.507Z", "_datatype" : "dateTime"}
        ]}
      , "answeringDeptId" : {"_value" : "17"}
      , "answeringDeptShortName" : {"_value" : "Health and Social Care"}
      , "answeringDeptSortName" : {"_value" : "Health and Social Care"}
      , "date" : {"_value" : "2018-12-13", "_datatype" : "dateTime"}
      , "hansardHeading" : {"_value" : "Orphan Drugs"}
      , "houseId" : {"_value" : "1"}
      , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
      }
      ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he is taking steps to introduce a revised definition for ultra-orphan medicine.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
      , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
      }
      , "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
      , "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
      ], "uin" : "202090"}
    ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}